Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type i interferon

Nature Communications

Volumn 5, Issue , 2014, Pages

  Ho, Bing Ching ^a   Yu, I Shing ^a   Lu, Li Fan ^b,c   Rudensky, Alexander ^c   Chen, Hsuan Yu ^d   Tsai, Chang Wu ^a   Chang, Yih Leong ^e   Wu, Chen Tu ^e   Chang, Luan Yin ^e   Shih, Shin Ru ^f   Lin, Shu Wha ^a,e   Lee, Chun Nan ^a,e   Yang, Pan Chyr ^a,e,g   Yu, Sung Liang ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b SECTION OF MOLECULAR BIOLOGY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA 146A; PROTEIN C FOS; PROTEIN C JUN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, MOUSE; MICRORNA; MIRN146 MICRORNA, MOUSE;

GENE EXPRESSION; IMMUNITY; INFECTIOUS DISEASE; INHIBITION; MITOCHONDRIAL DNA; NEUTRALIZATION; PATHOGENICITY; RODENT; SIGNAL; SURVIVAL; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; COXSACKIE VIRUS B3; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LUNG EDEMA; MALE; MOUSE; MYOSITIS; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; SURVIVAL RATE; UPREGULATION; VIRUS LOAD; VIRUS PATHOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DEATH; DRUG EFFECTS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84896838762     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4344     Document Type: Article

References (65)

1. Ryu, W. S. et al. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg. Infect. Dis. 16, 1764-1766 (2010).
2. Singh, S., Poh, C. L. & Chow, V. T. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol. Immunol. 46, 801-808 (2002). (Pubitemid 35428958)
3. Shimizu, H. et al. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J. Infect. Dis. 52, 12-15 (1999). (Pubitemid 29414613)
4. Solomon, T. et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet. Infect. Dis. 10, 778-790 (2010).
5. McMinn, P., Stratov, I., Nagarajan, L. & Davis, S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin. Infect. Dis. 32, 236-242 (2001). (Pubitemid 32524793)
6. Chang, L. Y., Huang, Y. C. & Lin, T. Y. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 352, 367-368 (1998).
7. Chang, L. Y. et al. Neurodevelopment and cognition in children after enterovirus 71 infection. New Engl. J. Med. 356, 1226-1234 (2007).
8. Huang, C. C. et al. Neurologic complications in children with enterovirus 71 infection. New Engl. J. Med. 341, 936-942 (1999).
9. Wang, Y. F. et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol. 78, 7916-7924 (2004).
10. Chang, L. Y. et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354, 1682-1686 (1999).
11. Kawai, T. & Akira, S. Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137 (2006). (Pubitemid 43135878)
12. Klotman, M. E. & Chang, T. L. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6, 447-456 (2006).
13. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T. P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999). (Pubitemid 29241123)
14. Le Bon, A. et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470 (2001). (Pubitemid 32441598)
15. Nguyen, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297, 2063-2066 (2002).
16. Tough, D. F., Sun, S., Zhang, X. & Sprent, J. Stimulation of naive and memory T cells by cytokines. Immunol. Rev. 170, 39-47 (1999). (Pubitemid 29490743)
17. Ichimura, H. et al. Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis. J. Med. Virol. 15, 231-237 (1985). (Pubitemid 15112094)
18. Liu, M. L. et al. Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 86, 3263-3269 (2005).
19. Levin, S. Interferon treatment of poliomyelitis. J. Infect. Dis. 151, 745-746 (1985).
20. Sasaki, O., Karaki, T. & Imanishi, J. Protective effect of interferon on infections with hand, foot, and mouth disease virus in newborn mice. J. Infect. Dis. 153, 498-502 (1986). (Pubitemid 16135653)
21. Deonarain, R., Cerullo, D., Fuse, K., Liu, P. P. & Fish, E. N. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110, 3540-3543 (2004). (Pubitemid 39612568)
22. Hung, H. C. et al. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J. Infect. Dis. 203, 1784-1790 (2011).
23. Yi, L., He, Y., Chen, Y., Kung, H. F. & He, M. L. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir. Ther. 16, 51-58 (2011).
24. Cullen, B. R. Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev. 25, 1881-1894 (2011).
25. Ho, B. C. et al. Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host. Microbe. 9, 58-69 (2011).
26. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 (2005). (Pubitemid 41266486)
27. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
28. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. New Engl. J. Med. 368, 1685-1694 (2013).
29. Sethupathy, P., Megraw, M. & Hatzigeorgiou, A. G. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 3, 881-886 (2006). (Pubitemid 44614721)
30. Wang, M. et al. Genetic variants in miRNAs predict bladder cancer risk and recurrence. Cancer Res. 72, 6173-6182 (2012).
31. Hou, J. et al. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1 and IRAK2. J. Immunol. 183, 2150-2158 (2009).
32. Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA 103, 12481-12486 (2006). (Pubitemid 44267285)
33. Miranda, K. C. et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126, 1203-1217 (2006). (Pubitemid 44380294)
34. Krek, A. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500 (2005). (Pubitemid 40617277)
35. Barde, I. et al. A KRAB/KAP1-miRNA cascade regulates erythropoiesis through stage-specific control of mitophagy. Science 340, 350-353 (2013).
36. Farre, D. et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31, 3651-3653 (2003). (Pubitemid 37442215)
37. Wasserman, W. W. & Sandelin, A. Applied bioinformatics for the identification of regulatory elements. Nat. Rev. Genet. 5, 276-287 (2004). (Pubitemid 38435623)
38. Matys, V. et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108-D110 (2006).
39. Rusca, N. et al. MiR-146a and NF-kappaB1 regulate mast cell survival and T lymphocyte differentiation. Mol. Cell Biol. 32, 4432-4444 (2012).
40. Yang, L. et al. miR-146a controls the resolution of T cell responses in mice. J. Exp. Med. 209, 1655-1670 (2012).
41. Pacifico, F. et al. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J. Clin. Endocrinol. Metab. 95, 1421-1430 (2010).
42. McMillan, D. H. et al. Attenuation of inflammatory mediator production by the NF-kappaB member RelB is mediated by microRNA-146a in lung fibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol. 304, L774-L781 (2013).
43. Kida, Y. et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 29, 159-168 (2005). (Pubitemid 40126234)
44. Huang, W., Batra, S., Korrapati, S., Mishra, V. & Mehta, K. D. Selective repression of low-density lipoprotein receptor expression by SP600125: coupling of histone H3-Ser10 phosphorylation and Sp1 occupancy. Mol. Cell Biol. 26, 1307-1317 (2006). (Pubitemid 43202558)
45. Costa-Mattioli, M. & Sonenberg, N. RAPping production of type I interferon in pDCs through mTOR. Nat. Immunol. 9, 1097-1099 (2008).
46. Lin, Y. W. et al. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J. Virol. 83, 6477-6483 (2009).
47. Singh, S., Chow, V. T., Phoon, M. C., Chan, K. P. & Poh, C. L. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J. Clin. Microbiol. 40, 2823-2827 (2002). (Pubitemid 35284947)
48. Khong, W. X. et al. A Non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86, 2121-2131 (2012).
49. Li, C. C. et al. Clinical manifestations and laboratory assessment in an enterovirus 71 outbreak in southern Taiwan. Scand. J. Infect. Dis. 34, 104-109 (2002).
50. Chen, C. S. et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J. Virol. 81, 8996-9003 (2007).
51. Zhang, Y. et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab. Invest. 91, 1337-1350 (2011).
52. Henke, J. I. et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 27, 3300-3310 (2008).
53. Jopling, C. L., Schutz, S. & Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host. Microbe. 4, 77-85 (2008). (Pubitemid 351944051)
54. Jangra, R. K., Yi, M. & Lemon, S. M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J. Virol. 84, 6615-6625 (2010).
55. Janssen, H. L. et al. Treatment of HCV infection by targeting MicroRNA. New Engl. J. Med. 368, 1685-1694 (2013).
56. Tyler, B. M. et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc. Natl Acad. Sci. USA 96, 7053-7058 (1999). (Pubitemid 29275008)
57. Yazaki, T. et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50, 236-242 (1996). (Pubitemid 26265126)
58. Ahmed, M. et al. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77, 4646-4657 (2003). (Pubitemid 36402814)
59. Chinsangaram, J., Piccone, M. E. & Grubman, M. J. Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. J. Virol. 73, 9891-9898 (1999).
60. Murphy, J. A., Duerst, R. J., Smith, T. J. & Morrison, L. A. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J. Virol. 77, 9337-9345 (2003). (Pubitemid 37011030)
61. Smiley, J. R. Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase? J. Virol. 78, 1063-1068 (2004). (Pubitemid 38095816)
62. Kim, M. J., Latham, A. G. & Krug, R. M. Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique. Proc. Natl Acad. Sci. USA 99, 10096-10101 (2002). (Pubitemid 34831178)
63. Ramanan, P. et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc. Natl Acad. Sci. USA 109, 20661-20666 (2012).
64. Aguirre, S. et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS. Pathog. 8, e1002934 (2012).
65. Weber, F., Kochs, G. & Haller, O. Inverse interference: how viruses fight the interferon system. Viral Immunol. 17, 498-515 (2004). (Pubitemid 40054230)